MIR425

Summary

MIR425 (microRNA 425, HGNC:31882) is a microRNA gene on chromosome 3p21.31.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 494337 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31882
Approved symbol	MIR425
Name	microRNA 425
Location	3p21.31
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-425
Ensembl gene	ENSG00000199032
Ensembl biotype	miRNA
Entrez	494337
RNAcentral	URS000075EE47 — miRNA, 87 nt, 13 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000362162

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000362162 — 1 exons

Exon	Start	End
ENSE00001436925	49020148	49020234

Expression profiles

Bgee: expression breadth broad, 81 present calls, max score 81.97.

Top tissues by expression

81 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	81.97	gold quality
bone marrow	UBERON:0002371	79.74	gold quality
monocyte	CL:0000576	79.61	gold quality
granulocyte	CL:0000094	78.93	gold quality
blood	UBERON:0000178	78.92	gold quality
adrenal tissue	UBERON:0018303	78.60	gold quality
placenta	UBERON:0001987	76.04	gold quality
myometrium	UBERON:0001296	75.26	gold quality
islet of Langerhans	UBERON:0000006	74.05	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	73.87	gold quality
right lobe of liver	UBERON:0001114	73.82	gold quality
liver	UBERON:0002107	72.71	gold quality
gastrocnemius	UBERON:0001388	72.19	gold quality
stomach	UBERON:0000945	71.83	gold quality
right testis	UBERON:0004534	71.54	gold quality
right adrenal gland cortex	UBERON:0035827	71.30	gold quality
body of stomach	UBERON:0001161	70.92	gold quality
heart	UBERON:0000948	70.88	gold quality
heart left ventricle	UBERON:0002084	70.19	gold quality
testis	UBERON:0000473	69.56	gold quality
right atrium auricular region	UBERON:0006631	69.27	gold quality
uterus	UBERON:0000995	68.72	gold quality
left testis	UBERON:0004533	68.63	gold quality
right adrenal gland	UBERON:0001233	68.56	gold quality
body of pancreas	UBERON:0001150	68.23	gold quality
endometrium	UBERON:0001295	68.04	gold quality
omental fat pad	UBERON:0010414	67.85	gold quality
fundus of stomach	UBERON:0001160	67.78	gold quality
esophagus mucosa	UBERON:0002469	67.78	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	67.72	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.00

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• Data suggest that the variant rs1425486 genotype could differentially affect targeting by miR-425 in ovarian cancer cells leading to higher PDGFC expression. (PMID:21118967)
• in vitro and in vivo experiments demonstrated that miR-191 and miR-425 reduced proliferation, impaired tumorigenesis and metastasis, and increased expression of epithelial markers in aggressive breast cancer cells (PMID:23505378)
• MiR-425 silences NPPA mRNA in an allele-specific manner. (PMID:23867623)
• our data support a critical role for NF-kappaB-dependent upregulation of miR-425, which represents a new pathway for the repression of phosphatase and tensin homolog activation and the promotion of cell survival upon IL-1beta induction. (PMID:24571667)
• Data indicate the oncogenic roles of miR-191 and miR-425 in gastric carcinogenesis, and the potential use of serum miR-191 as a biomarker for gastric cancer (GC) diagnosis. (PMID:24603541)
• Results identify and characterize a new role for miR425, miR1, miR125, and miR150 in promoting radioresistance in glioblastomas. (PMID:25256711)
• miR-425 may function as a tumor suppressor in melanoma by targeting IGF-1 signaling pathway, to prevent metastasis. (PMID:26463631)
• MiR-425-5p regulates chemoresistance. (PMID:26647742)
• MiR-425 functions as an oncogene by targeting the 3’-UTR of SMAD2 in esophageal squamous cell carcinoma. (PMID:26674378)
• miR-24-3p, miR-151a-5p, and miR-425-5p have been identified as the most valid combination of reference genes for microRNA RT-qPCR studies in a hepatitis B virus replicating HepG2 cell model. (PMID:26801621)
• High miR425 expression is associated with hepatocellular carcinoma. (PMID:26882563)
• High miR425 expression is associated with lung adenocarcinoma. (PMID:27036025)
• Inhibition of Notch and activation of VEGF/p38 signaling were involved in miR-425-5p/CCM3 mediated inhibition of angiogenesis by sodium arsenite. (PMID:27132035)
• The study suggests that miR-425-5p is up-regulated in cervical cancer, and serum miR-425-5p may serve as a potential prognostic biomarker for cervical cancer. (PMID:27166306)
• Data indicate that serum levels of microRNAs miR-19a-3p, miR-21-5p and miR-425-5p were significantly higher in patients with colorectal cancer (CRC) than in normal control (NC). (PMID:28177881)
• in vitro assays confirmed that decreased miR-425 strongly induced inflammatory cytokines (interleukin [IL]-2 and interferon [IFN]-gamma) via N-Ras upregulation in the TCR signalling pathway in primary biliary cholangitis (PMID:28192189)
• These results indicate that miR-425-5p facilitates EMT and extracellular matrix degradation and promotes HCC metastasis through SCAI-mediated dysregulation of multiple signaling pathways. (PMID:28423650)
• mirn 146a/b-5 and 425-3p and 24-3p may have roles in response to antidepressants and in regulating MAPK/Wnt-system genes (PMID:28530238)
• Our findings indicate that miR-425-5p may contribute to the progression of gastric cancer, through a mechanism involving CYLD (PMID:28537672)
• miR-425-5p can be considered as a marker of poor prognosis and it is probably involved in gastric cancer cell proliferation and apoptosis. (PMID:28647207)
• Our results show that miR-425-5p, miR-21 and miR-212 significantly decreased in centenarians and in patients with rheumatoid arthritis compared with controls (PMID:28824293)
• Expression levels of six reference microRNAs-hsa-miR-425-5p, hsa-miR-191-5p, hsa-miR-93-5p, hsa-miR-423-5p, hsa-miR-103a-3p, and hsa-miR-16-5p-were analyzed in plasma from vulvar intraepithelial neoplasia lesion and vulvar squamous cell carcinoma. (PMID:29299981)
• The data reveal a novel mechanism in which the elevated miR-425 in IBD mediates pathogenic Th17 cell generation through down-regulation of Foxo1. (PMID:29331376)
• High miR-425-3p proved to be a potent predictive biomarker for low responsiveness of non-small cell lung cancer to platinum-cased chemotherapy and poor progression-free survival. Mechanistically, miR-425-3p upregulated the autophagic levels via targeting AKT1, leading to the decrease in therapeutic response. (PMID:30228154)
• The expression of miR-425 may be useful in identifying patients in need of strategies to select the optimal therapy between chemotherapy and allo-hematopoietic stem cell transplantation treatment regimens. (PMID:30285885)
• Data found that miR-425 expression was decreased in clear cell renal carcinoma (ccRCA) tumor tissues and that miR-425 could inhibit the growth and promote the apoptosis of ccRCA cells by targeting E2F6. (PMID:30338798)
• Reduced exosome miR-425 and miR-744 in the plasma represents the progression of fibrosis and heart failure (PMID:30392569)
• MicroRNA-425-5p promotes the development of prostate cancer via targeting forkhead box J3. (PMID:30720162)
• miR-425-5p suppressed the tumorigenesis of OS via decreasing MALAT1 and TUG1 expressions through inactivation of the Wnt/beta-catenin signaling pathway (PMID:30986552)
• LINC-PINT targeted miR-425-5p by three sites. miR-425-5p also targeted PTCH1 a protein of the Hedgehog pathway. Downregulation of LINC-PINT was associated with increased cancer stemness and chemoresistance to cisplatin. (PMID:31131448)
• the present results demonstrated that miR4255p promoted hepatocellular carcinoma (HCC) cell proliferation, migration, and invasion by suppressing FOXD3 expression, potentially providing a novel target for the treatment of HCC. (PMID:31257522)
• MiR-425 deficiency and necroptosis activation were confirmed in dopaminergic neuron in the brains of Parkinson’s disease patients. (PMID:31383850)
• In vivo experiments, recovery of GSK3beta prevented xenograft tumor growth and DDP resistance in the presence of miR-425-5p mimic. To sum up, miR-425-5p upregulation might sensitize human PCa to DDP by targeting GSK3beta and inactivating the Wnt/beta-catenin signaling pathway. (PMID:31502580)
• miR4255p expression was increased in breast cancer (BC) tissues and cell lines, and was associated with tumor size, clinical stage, lymph node metastasis, distant metastasis and poor overall survival in patients with BC. Knockdown of miR4255p in BC cell lines inhibited proliferation and migration. PTEN was identified as a downstream target gene of miR4255p. (PMID:31638259)
• Our results underlined that miR-425-5p might act as an oncogene to participate in the pathogenesis of KRAS-mutated CRC and contribute to increase the aggressiveness of this subcategory of CRC, controlling a complex molecular network (PMID:31673240)
• miR-425 promotes the proliferation/invasion and suppresses apoptosis by targeting AMPH-1 in non-small-cell lung cancer cells. (PMID:31685299)
• MicroRNA-425-5p promotes breast cancer cell growth by inducing PI3K/AKT signaling. (PMID:31688991)
• The NF-kappaB/miR-425-5p/MCT4 axis: A novel insight into diabetes-induced endothelial dysfunction. (PMID:31711985)
• Overexpression of miR-425-5p predicts poor prognosis of non-small lung cancer and promotes cancer cell proliferation, migration and invasion by targeting FOXJ3. (PMID:31771046)
• This study identified increased MALAT1 and decreased miR-425 in ARDS patients. MALAT1 interacted with miR-425 and protected phosphatase and tensin homolog (PTEN) expression. (PMID:31871512)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Mir425	ENSMUSG00000065579
rattus_norvegicus	Mir425	ENSRNOG00000035484

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.